DBV Technologies SA (FRA:DBV)

€ 0.65 0.04 (6.56%) Market Cap: 64.46 Mil Enterprise Value: 28.17 Mil PE Ratio: 0 PB Ratio: 1.32 GF Score: 36/100

Half Year 2024 Dbv Technologies SA Earnings Call Transcript
Jul 30, 2024

€0.832 (+0.24%)

Earnings
Full Year 2023 Dbv Technologies SA Earnings Call Transcript
Mar 07, 2024

€1.39 (-0.64%)

Earnings
Dbv Technologies SA to Discuss the EPOPEX Data Call Transcript
Nov 09, 2023
Q3 2023 Dbv Technologies SA Earnings Call Transcript
Oct 31, 2023

Earnings
Half Year 2023 Dbv Technologies SA Earnings Call Transcript
Jul 31, 2023

€2.89 (-3.35%)

Earnings
Dbv Technologies SA at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Dbv Technologies SA at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Dbv Technologies SA FDA Regulatory Call Transcript
Apr 19, 2023
Full Year 2022 Dbv Technologies SA Earnings Call Transcript
Mar 02, 2023

€2.75 (-0.15%)

Earnings
Q3 2022 Dbv Technologies SA Earnings Call Transcript
Nov 03, 2022

€2.84 (-2.00%)

Earnings
Dbv Technologies SA to Discuss the VITESSE Study Call Transcript
Sep 07, 2022
Dbv Technologies SA to Discuss Positive Topline Results from Phase 3 EPITOPE Trial Call Transcript
Jun 07, 2022
Q1 2022 DBV Technologies SA Earnings Call Transcript
May 02, 2022

€2.57 (+4.39%)

Earnings
Full Year 2021 DBV Technologies SA Earnings Call Transcript
Mar 03, 2022

€2.78 (+17.49%)

Earnings
DBV Technologies SA Provides Update on Investigational Viaskin™ Peanut Corporate Call Transcript
Dec 20, 2021
Q3 2021 DBV Technologies SA Earnings Call Transcript
Oct 26, 2021

€8.62 (-4.22%)

Earnings
Half Year 2021 DBV Technologies SA Earnings Call Transcript
Aug 02, 2021

€9.11 (+1.02%)

Earnings
DBV Technologies SA at JMP Securities Life Sciences Virtual Conference Transcript
Jun 16, 2021
DBV Technologies SA at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Full Year 2020 DBV Technologies SA Earnings Call Transcript
Mar 11, 2021

€8.85 (-2.86%)

Earnings
DBV Technologies SA at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 24, 2021
DBV Technologies SA To Provide An Update On Investigational Viaskin Peanut for Children Ages 4-11 Years Call Transcript
Jan 14, 2021
DBV Technologies SA at Evercore ISI HealthCONx Conference Transcript
Dec 01, 2020
DBV Technologies SA at Stifel Virtual Healthcare Conference Transcript
Nov 16, 2020
DBV Technologies SA at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2020
DBV Technologies SA at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
DBV Technologies SA at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2020
DBV Technologies SA - Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years - Conference Call Transcript
Mar 16, 2020
DBV Technologies SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2019
DBV Technologies SA at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
DBV Technologies SA at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
DBV Technologies SA To Provide Update on Regulatory Status of Viaskin Peanut for the Treatment of Peanut-Allergic Children Corporate Call Transcript
Feb 13, 2019

Dbv Technologies SA to Discuss the EPOPEX Data Call Transcript

Nov 09, 2023 / 10:00PM GMT

Release Date Price: €1.9 (-0.78%)

Transcript

Operator

Welcome to the DBV Technologies Interim Results from the open-label extension to EPITOPE Phase III trial Conference Call.

(Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Katie Matthews, Investor Relations. Please go ahead.

Katie Matthews

Thank you. This afternoon, DBV Technologies issued a press release announced the interim results from our ongoing open-label extension to the EPITOPE Phase III trial, DBV's prior Phase III efficacy study, which evaluated Viaskin Peanut in toddlers ages 1 to 3 years old. This press release is available in the Press Releases section of the DPV Technologies website.

Before we begin, please note that today's call may include a number of forward-looking statements, including, but not limited to comments regarding the therapeutic potential of Viaskin Peanut and EPIT, our clinical and regulatory development plans, the timing and results of interactions with regulatory agencies, our forecast of our runway and the ability of any of our product

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.